CVS Health and Aetna executives defended their $69 billion proposed merger before the California insurance commissioner on Tuesday, as a panel of antitrust experts and healthcare providers chipped away at the companies’ promise to lower U.S. healthcare costs and improve the quality of care without harming competition.
Although California Insurance Commissioner Dave Jones doesn’t have direct approval authority over the merger because Aetna isn’t based in California, his opinion could influence how other state regulators view the deal.
Antitrust experts and provider organization representatives who testified at the hearing spoke against the merger. Dr. Barbara McAneny, president of the American Medical Association and an oncologist in Albuquerque, told Jones that the AMA is recommending that state and federal regulators block the proposed merger after an analysis found it “would substantially lessen competition in many healthcare markets to the detriment of patients.”
The association’s analysis concluded the deal would increase premiums for Medicare Part D drug plans and increase drug spending and out-of-pocket costs. Speaking as a physician, McAneny also argued that the merger would make it harder for oncologists to care for patients by increasing the price of already expensive specialty pharmaceutical drugs used to treat complex diseases like cancer, cystic fibrosis and autoimmune diseases
Full Content: Modern HealthCare
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI